Non-metastatic Prostate Cancer Epidemiology Insights & Trends

• Prostate cancer happens when abnormal cells form and grow in the prostate gland. Unlike benign (or non-cancerous) growths, these growths are cancerous (malignant). Prostate cancer can be life-threatening if it becomes “metastatic” and spreads beyond the prostate. Early stages of prostate cancer rely on testosterone to grow; sometimes, lowering testosterone can control growth.
• Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. If prostate cancer is diagnosed as CRPC, it can grow or spread even with low testosterone levels, and with non-metastatic CRPC (nmCRPC), the cancer no longer responds to hormone treatment. It shows signs of growth, like a rising PSA (prostate-specific antigen) level, but it is only found in the prostate and has not spread.
• Often, there are no symptoms for patients with nmCRPC. Most men cannot tell if the cancer is growing unless the doctor notices a rise in the PSA level. Changes are tracked with blood tests, physical exams, and scans, such as CT Scans, bone, and PET scans.
• Approximately one in nine men in the US is diagnosed with this disease at some point. As per the American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.

Non-metastatic Prostate Cancer (nmPC) Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Prostate Cancer: ~386,000
• 2036 Diagnosed Prevalent Cases of Prostate Cancer: ~XXXX
• Prostate Diagnosed Cancer Growth Rate (2026–2036): 2.8% CAGR

DelveInsight's "Non-metastatic Prostate Cancer Epidemiology Forecast – 2036" report delivers an in-depth understanding of the Non-metastatic Prostate Cancer (nmPC), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Non-metastatic Prostate Cancer Understanding and Diagnosis Algorithm

Non-metastatic Prostate Cancer (nmPC) Overview

Non-metastatic prostate cancer is confined to the prostate or nearby tissues, without distant spread. It’s often asymptomatic and detected via elevated PSA or abnormal DRE. Diagnosis is confirmed by biopsy, with imaging used to assess local spread. Risk is stratified by PSA, Gleason score, and tumor stage, guiding treatment options like active surveillance, surgery, or radiation. Early detection generally leads to a favorable prognosis.

Non-metastatic Prostate Cancer (nmPC) Diagnosis

Diagnosis of Non-metastatic Prostate Cancer is based on a combination of clinical evaluation and diagnostic testing. It is typically suspected in men with elevated prostate-specific antigen (PSA) levels or abnormal findings on digital rectal examination (DRE). Confirmation is achieved through a prostate biopsy, which determines tumor grade and aggressiveness. Imaging techniques such as multiparametric MRI are used to assess local tumor extent, while CT scans or bone scans help rule out distant metastasis, ensuring accurate staging and appropriate treatment planning.

Further details are provided in the report...

Non-metastatic Prostate Cancer Epidemiology

The Non-metastatic Prostate Cancer epidemiology section offers a comprehensive analysis of the historical, current, and forecasted patient population across the seven major markets (7MM). It examines key factors influencing epidemiological trends by incorporating findings from published research, expert opinions, and insights from key opinion leaders (KOLs). The section also presents estimates of the diagnosed patient population, highlights evolving disease trends, and outlines the assumptions and methodologies used to generate the epidemiological forecasts.

Key Findings from Non-metastatic Prostate Cancer (nmPC) Epidemiological Analysis and Forecast

• Approximately one in nine men in the US is diagnosed with this disease at some point. As per the American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
• The majority of prostate cancer cases are diagnosed before distant spread, with approximately 70% of cases identified at a localized (non-metastatic) stage in the United States, reflecting the impact of early detection and PSA-based screening.

Scope of the Non-metastatic Prostate Cancer Epidemiology Report

• The report covers a segment of an executive summary, a descriptive overview of nmPC, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Non-metastatic Prostate Cancer Epidemiology Report Insights

Non-metastatic Prostate Cancer(nmPC) Patient Population Forecast

Non-metastatic Prostate Cancer Epidemiology Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

Make informed strategic decisions with DelveInsight's nmPC Market Insight, Epidemiology and Market Forecast–2036, covering emerging therapies, market trends, and growth opportunities.

FAQs

• What are the disease risks, burdens, and unmet needs of nmPC? What will be the growth opportunities across the 7MM concerning the patient population with nmPC?
• What is the historical and forecasted Ewing sarcoma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy Non-metastatic Prostate Cancer Epidemiology Report

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.